Form 4: BioLife CEO De Greef Boosts Stake via Performance Awards

BioLife Solutions Inc. CEO Roderick de Greef acquired over 500,000 shares through restricted stock awards, demonstrating strong performance-based vesting.

Summary

• Roderick de Greef, President and CEO of BioLife Solutions Inc., acquired a total of 508,045 shares of common stock through various restricted stock awards on February 24, 2026.
• 118,730 shares were granted as part of 2026 compensation, vesting 25% on the first anniversary of the grant date and thereafter quarterly in 12 equal installments.
• 170,291 shares vested based on the registrant's total shareholder return (TSR) during January 1, 2024, through December 31, 2025, achieving approximately 156% of the number of shares granted.
• 219,024 shares vested based on specific performance metrics of the registrant during January 1, 2024, through December 31, 2025, achieving 200% of the number of shares granted.
• De Greef disposed of 153,196 shares (67,010 shares at $22.65 and 86,186 shares at $22.65) to cover tax withholding obligations related to the vesting of these restricted stock awards.
• Following these transactions, Roderick de Greef's direct beneficial ownership of common stock increased to 744,847 shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively as it reflects strong company performance, leading to significant vesting of performance-based executive compensation and increased insider ownership.

Positives

• Significant vesting of restricted stock awards indicates the company met or exceeded performance targets, including total shareholder return and specific operational metrics.
• The vesting at approximately 156% for Total Shareholder Return (TSR) and 200% for specific performance metrics suggests strong company performance over the 2024-2025 period.
• The acquisition of 508,045 shares by the CEO increases his direct stake in the company, aligning his interests with shareholders.

Negatives

• The disposition of 153,196 shares to cover tax withholding obligations represents a reduction in the CEO's direct ownership that is not a discretionary sale.

Industry Context

StockSavvy.ai notes that executive compensation tied to performance metrics and total shareholder return is a common practice in the biotechnology and life sciences industry, aiming to align management incentives with long-term shareholder value creation. The high vesting percentages suggest BioLife Solutions performed strongly relative to its peers and internal targets during the specified period.

Comparison to Industry Standards

• The vesting of restricted stock at approximately 156% based on Total Shareholder Return (TSR) compared to peers indicates BioLife Solutions outperformed a significant portion of its peer group. For example, a typical 'at target' vesting would be 100%, so 156% suggests strong relative performance.
• The vesting at 200% based on specific performance metrics implies the company significantly exceeded its internal operational or strategic goals. This level of achievement is often seen in companies demonstrating exceptional execution or market capture, potentially comparable to top-tier performers in the cell and gene therapy tools sector.

Related Party Transactions

• The restricted stock grants and subsequent vesting are transactions between the company and its CEO, which are considered related-party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The significant vesting of performance-based awards suggests strong company performance, which is generally positive for shareholders. Increased insider ownership also aligns management interests with shareholders.
• Employees: Strong company performance leading to executive compensation success can signal a healthy company environment, potentially boosting employee morale and future opportunities.

Next Steps

• The 118,730 shares granted as 2026 compensation will vest 25% on the first anniversary of the grant date and thereafter quarterly in 12 equal installments.

Key Dates

Recommendation

The significant vesting of performance-based restricted stock awards at approximately 156% for TSR and 200% for specific performance metrics indicates exceptional company performance during the 2024-2025 period. This strong execution, coupled with the CEO's increased beneficial ownership, suggests robust operational health and strong alignment of management incentives with shareholder value. Such positive indicators warrant a 'strong buy' recommendation for long-term investors.

Keywords

BioLife Solutions, BLFS, Roderick de Greef, SEC Form 4, Insider Trading, Restricted Stock, Performance Awards, Executive Compensation, Shareholder Return, Stock Vesting